Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Non-Current Deffered Revenue: 2010-2016

Historic Non-Current Deffered Revenue for Anika Therapeutics (ANIK) over the last 6 years, with Dec 2016 value amounting to $48,000.

  • Anika Therapeutics' Non-Current Deffered Revenue fell 27.27% to $48,000 in Q4 2016 from the same period last year, while for Dec 2016 it was $48,000, marking a year-over-year decrease of 27.27%. This contributed to the annual value of $48,000 for FY2016, which is 27.27% down from last year.
  • Per Anika Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $48,000 for Q4 2016, which was down 18.64% from $59,000 recorded in Q3 2016.
  • Anika Therapeutics' 5-year Non-Current Deffered Revenue high stood at $4.3 million for Q1 2012, and its period low was $48,000 during Q4 2016.
  • Its 3-year average for Non-Current Deffered Revenue is $69,019, with a median of $68,723 in 2014.
  • In the last 5 years, Anika Therapeutics' Non-Current Deffered Revenue plummeted by 97.21% in 2014 and then spiked by 30.74% in 2015.
  • Anika Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $2.2 million in 2012, then fell by 4.54% to $2.1 million in 2013, then tumbled by 95.04% to $102,000 in 2014, then tumbled by 35.29% to $66,000 in 2015, then decreased by 27.27% to $48,000 in 2016.
  • Its Non-Current Deffered Revenue stands at $48,000 for Q4 2016, versus $59,000 for Q3 2016 and $56,000 for Q2 2016.